Compare PAX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | NUVB |
|---|---|---|
| Founded | 1988 | 2018 |
| Country | Cayman Islands | United States |
| Employees | N/A | 291 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | PAX | NUVB |
|---|---|---|
| Price | $11.27 | $4.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $20.00 | $11.38 |
| AVG Volume (30 Days) | 896.3K | ★ 4.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.28% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.00 | $182.76 |
| Revenue Next Year | $15.87 | $91.83 |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.44 | $1.57 |
| 52 Week High | $17.80 | $9.75 |
| Indicator | PAX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 21.97 | 32.94 |
| Support Level | $10.12 | $4.04 |
| Resistance Level | $14.53 | $5.73 |
| Average True Range (ATR) | 0.42 | 0.29 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 3.76 | 6.61 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.